We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Expanded Access to Venetoclax

Expanded access is currently available for this treatment.
Verified April 2017 by AbbVie
Sponsor:
ClinicalTrials.gov Identifier:
NCT03123029
First Posted: April 21, 2017
Last Update Posted: April 21, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
Information provided by (Responsible Party):
AbbVie
  Purpose
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Venetoclax prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Condition Intervention
Chronic Lymphocytic Leukemia (CLL) Multiple Myeloma Acute Myeloid Leukemia (AML) Non-Hodgkin's Lymphoma Drug: Venetoclax

Study Type: Expanded Access     What is Expanded Access?
Available for Individual Patients
Official Title: Expanded Access to Venetoclax

Resource links provided by NLM:


Further study details as provided by AbbVie:

Intervention Details:
    Drug: Venetoclax
    Venetoclax will be administered orally.
    Other Names:
    • ABT-199
    • GDC-0199
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Criteria
  • The participant must not be eligible for a venetoclax clinical trial.
  • Pediatric participants may be evaluated on a case by case basis.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03123029


Contacts
Contact: AbbVie_Call Center 847-283-8955 abbvieclinicaltrials@abbvie.com

Sponsors and Collaborators
AbbVie
Investigators
Study Director: AbbVie Inc. AbbVie
  More Information

Responsible Party: AbbVie
ClinicalTrials.gov Identifier: NCT03123029     History of Changes
Other Study ID Numbers: C16-431
First Submitted: April 18, 2017
First Posted: April 21, 2017
Last Update Posted: April 21, 2017
Last Verified: April 2017

Keywords provided by AbbVie:
Expanded Access
Pre-approval Access
Compassionate Use
Special Access Program
Named Patient Basis
Special Access Scheme

Additional relevant MeSH terms:
Leukemia
Leukemia, Myeloid, Acute
Multiple Myeloma
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Neoplasms by Histologic Type
Neoplasms
Leukemia, Myeloid
Neoplasms, Plasma Cell
Hemostatic Disorders
Vascular Diseases
Cardiovascular Diseases
Paraproteinemias
Blood Protein Disorders
Hematologic Diseases
Hemorrhagic Disorders
Lymphoproliferative Disorders
Immunoproliferative Disorders
Immune System Diseases
Lymphoma
Lymphatic Diseases
Leukemia, B-Cell
Venetoclax
Antineoplastic Agents